• Imago BioSciences Completes Enrollment in IMG-7289 Study americanpharmaceuticalreview
    August 22, 2018
    Imago BioSciences announced the Phase 1/2a clinical trial of IMG-7289 for the treatment of high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) has fully enrolled at 45 patients.
PharmaSources Customer Service